KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $102000.0.

  • TherapeuticsMD's Income towards Parent Company rose 34285.71% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $229000.0, marking a year-over-year decrease of 6482.33%. This contributed to the annual value of $131000.0 for FY2024, which is 10507.95% up from last year.
  • Latest data reveals that TherapeuticsMD reported Income towards Parent Company of $102000.0 as of Q3 2025, which was up 34285.71% from $6000.0 recorded in Q2 2025.
  • TherapeuticsMD's 5-year Income towards Parent Company high stood at $127.2 million for Q2 2022, and its period low was -$47.4 million during Q3 2021.
  • For the 5-year period, TherapeuticsMD's Income towards Parent Company averaged around $1.6 million, with its median value being -$28500.0 (2024).
  • As far as peak fluctuations go, TherapeuticsMD's Income towards Parent Company soared by 39811.97% in 2022, and later crashed by 12266.67% in 2025.
  • Over the past 5 years, TherapeuticsMD's Income towards Parent Company (Quarter) stood at $50.2 million in 2021, then tumbled by 41.68% to $29.2 million in 2022, then crashed by 97.75% to $658000.0 in 2023, then plummeted by 79.03% to $138000.0 in 2024, then fell by 26.09% to $102000.0 in 2025.
  • Its Income towards Parent Company stands at $102000.0 for Q3 2025, versus $6000.0 for Q2 2025 and -$17000.0 for Q1 2025.